Syros Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2024
-
Advancement of tamibarotene for higher-risk MDS is on track, with pivotal Phase 3 data expected in mid-November. Q3 2024 saw reduced expenses and a narrowed net loss, with cash reserves projected to fund operations into Q3 2025.
-
A novel oral therapy targeting RARA overexpression in high-risk MDS is nearing pivotal phase III readout, with strong efficacy and safety data supporting potential first-to-market status. Preparations for U.S. launch and regulatory submission are underway.
-
Tamibarotene development advances with pivotal MDS and AML data expected in late 2024. Expenses and net loss declined year-over-year, with a cash runway into Q3 2025 supporting key milestones. U.S. commercialization is prioritized, with European partnering planned.
-
Tamibarotene is positioned as a novel, targeted therapy for higher-risk MDS with RARA overexpression, showing rapid, durable responses and favorable safety in clinical trials. The pivotal SELECT-MDS-1 phase III trial is expected to read out in Q4 2024, with experts viewing a significant CR rate as sufficient for adoption. Commercialization plans are underway, supported by a companion diagnostic.